Enhanced Investments - Financial Portal

Verge Genomics Honored by Goldman Sachs for Entrepreneurship

Published: 2022-10-12 12:00:00 ET

Alice Zhang, Chief Executive Officer and Co-Founder, Among the Most Exceptional Entrepreneurs at 2022 Builders and Innovators Summit

SAN FRANCISCO--(BUSINESS WIRE)-- Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that Goldman Sachs (NYSE:GS) is recognizing Verge’s Chief Executive Officer and co-founder, Alice Zhang, as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California.

Goldman Sachs selected Zhang from leaders and entrepreneurs across multiple industries. Verge deeply integrates new advances in hardware, software, and molecular technologies across the entire drug development process to find better drugs, faster. The company pursues a simple but radical premise: to successfully develop medicines for humans, we need to start with humans. Alice has been recognized for her work as a Forbes 30 Under 30 Featured Honoree, MIT Technology Review’s Innovator Under 35, and the San Francisco Business Times’ 40 Under 40. She currently sits on the board of directors at the California Life Sciences Association. Prior to Verge, she spent five years in the UCLA-Caltech MD/PhD program and received her BA degree from Princeton University in Molecular Biology. Alice also is an angel investor and advisor for over 20 tech-enabled bio startups.

“I’m grateful to Goldman Sachs to be recognized alongside such outstanding entrepreneurs that are working to make a positive impact on society in so many diverse areas,” said Zhang. “It is exciting to see the new opportunities for growth and innovation created by these individuals who are shaping the futures of their industries.”

“We’re delighted to recognize Alice Zhang as one of the most exceptional entrepreneurs of 2022,” said David M. Solomon, Chairman and CEO of Goldman Sachs. “They have made extraordinary contributions to a wide range of fields, and all of us are looking forward to meeting with these innovative thinkers.”

In addition to honoring the most exceptional entrepreneurs, the Summit consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About Verge GenomicsVerge uses AI and human data to develop better drugs faster for the most challenging diseases of our generation. Verge has built CONVERGE™, an end-to-end drug discovery and development platform, that integrates multiple technological innovations from discovery to translation to streamline drug development. Its pioneering use of the industry’s most advanced all-in-human AI-powered drug discovery platform identifies new medicines more efficiently and with an improved probability of success.

Verge is one of the first AI-enabled drug discovery companies to internally develop a clinical candidate from a novel target discovered from its platform. Verge has further demonstrated the power of CONVERGE™ by delivering a broad pipeline spanning diverse therapeutic areas, with its first program, an investigational PIKfyve inhibitor for the treatment of ALS, expected to enter the clinic in 2022. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.

For additional information, please visit www.vergegenomics.com. Follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005116/en/

Verge GenomicsAdam Silverstein Scient PR adam@scientpr.com

Goldman SachsSophia AnthonySophia.Anthony@gs.com

Source: Verge Genomics

Enhanced Investments, Inc.
329 South Oyster Bay Road #2085
Plainview, NY 11803
team@eninvs.com

Important disclosures

Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.

Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities.
Past performance is no guarantee of future results. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance.
All the strategies assume investments in equity invstrumenta only and are more relevant for "agressive investment profile". Eastern European flagship strategy assumes using up to 20% leverage of total portfolio. GlobalCommodities and US Growth strategy currently assume no leverage.
Results for the Enhanced Investments strategies as compared to the performance of Illustrative Benchmarks is for informational purposes only. Our investment program does not mirror that of the Illustrative Benchmarks and the volatility may be materially different from the volatility of Illustrative Benchmarks. Reference or comparison to an Illustrative Benchmark does not imply that strategies of Enhanced Investments will be constructed in the same way as the Illustrative Benchmark or achieve returns, volatility, or other results similar to those of the Illustrative Benchmark. The S&P 500 is an unmanaged market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.
Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.